Bolt Biotherapeutics Share Price (NASDAQ: BOLT)

$5.13

▲

-0.17

(-3.21%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Bolt Biotherapeutics Stock chart to analyse performance

Bolt Biotherapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$5.13
Today's High:$5.19
$5.13
0.0%
Downside
Day's Volatility :1.16%
Upside
1.16%
52 Weeks Low:$4.59
52 Weeks High:$14.36
$5.13
10.53%
Downside
52 Weeks Volatility :68.04%
Upside
64.28%

Bolt Biotherapeutics Stock Returns

Period	Bolt Biotherapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-15.06%	3.6%	0.0%
6 Months	-41.25%	-7.7%	0.0%
1 Year	-61.83%	-12.6%	0.0%
3 Years	-85.58%	10.2%	-4.1%

Bolt Biotherapeutics Inc Key Stats

Check Bolt Biotherapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$5.3
Open	$5.19
Today's High	$5.19
Today's Low	$5.13
Market Capitalization	$10.3M
Today's Volume	$4.8K
52 Week High	$14.36
52 Week Low	$4.59
Revenue TTM	$4.2M
EBITDA	$-51.8M
Earnings Per Share (EPS)	$-26.17
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-81.33%

Stock Returns calculator for Bolt Biotherapeutics Stock including INR - Dollar returns

The Bolt Biotherapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Bolt Biotherapeutics investment value today

Current value as on today

₹43,005

Returns

₹56,995

(-57%)

Returns from Bolt Biotherapeutics Stock

₹62,279 (-62.28%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Bolt Biotherapeutics Stock

25%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Bolt Biotherapeutics Stock from India on INDmoney has increased by 25% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Bolt Biotherapeutics Inc

Name
Holdings %
Name
Holdings %
Vivo Capital, LLC
9.17%
TANG CAPITAL MANAGEMENT LLC
8.69%
Sofinnova Ventures
7.18%
Pivotal bioVenture Partners Investment Advisor LLC
4.93%
Vanguard Group Inc
3.05%
Samsara BioCapital, LLC
2.73%

Analyst Recommendation on Bolt Biotherapeutics Stock

Rating

Trend

Buy

83%Buy

16%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Bolt Biotherapeutics(by analysts ranked 0 to 5 stars)

Bolt Biotherapeutics Share Price Target

What analysts predicted

Upside of 647.24%

Target:

$38.33

Current:

$5.13

Bolt Biotherapeutics share price target is $38.33, a slight Upside of 647.24% compared to current price of $5.13 as per analysts' prediction.

Bolt Biotherapeutics Stock Insights

Price Movement
In the last 6 months, BOLT stock has moved down by -45.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.22M → 1.80M (in $), with an average increase of 32.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -15.93M → -8.56M (in $), with an average increase of 36.7% per quarter
BOLT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 131.6%
BOLT vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.0% return, outperforming this stock by 201.6%
Price to Sales
ForBOLT every $1 of sales, investors are willing to pay $2.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Bolt Biotherapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$215.0K	-
Net Income	$-30.0M	↑ 158.91%
Net Profit Margin	-14.0K%	-

	FY20	Y/Y Change
Revenue	$231.0K	↑ 7.44%
Net Income	$-72.3M	↑ 140.87%
Net Profit Margin	-31.3K%	↓ 17331.64%

	FY21	Y/Y Change
Revenue	$1.3M	↑ 445.45%
Net Income	$-104.4M	↑ 44.44%
Net Profit Margin	-8.3K%	↑ 23002.21%

	FY22	Y/Y Change
Revenue	$5.7M	↑ 354.68%
Net Income	$-85.9M	↓ 17.74%
Net Profit Margin	-1.5K%	↑ 6786.29%

	FY23	Y/Y Change
Revenue	$7.9M	↑ 37.48%
Net Income	$-69.2M	↓ 19.42%
Net Profit Margin	-878.58%	↑ 620.37%

	FY24	Y/Y Change
Revenue	$7.7M	↓ 2.36%
Net Income	$-63.1M	↓ 8.79%
Net Profit Margin	-820.78%	↑ 57.8%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$5.3M	↑ 152.47%
Net Income	$-10.8M	↓ 39.61%
Net Profit Margin	-204.99%	↑ 652.02%

	Q2 FY24	Q/Q Change
Revenue	$1.3M	↓ 75.82%
Net Income	$-21.2M	↑ 96.05%
Net Profit Margin	-1.7K%	↓ 1457.36%

	Q3 FY24	Q/Q Change
Revenue	$1.1M	↓ 10.51%
Net Income	$-15.2M	↓ 28.4%
Net Profit Margin	-1.3K%	↑ 332.29%

	Q4 FY24	Q/Q Change
Revenue	$24.1M	↑ 2011.48%
Net Income	$-15.9M	↑ 5.01%
Net Profit Margin	-66.15%	↑ 1263.91%

	Q1 FY25	Q/Q Change
Revenue	$1.2M	↓ 94.93%
Net Income	$-11.0M	↓ 30.72%
Net Profit Margin	-903.44%	↓ 837.29%

	Q2 FY25	Q/Q Change
Revenue	$1.8M	↑ 47.63%
Net Income	$-8.6M	↓ 22.45%
Net Profit Margin	-474.56%	↑ 428.88%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-25.8M	↑ 8438.74%

	FY20	Y/Y Change
Profit	$-40.1M	↑ 55.61%

	FY21	Y/Y Change
Profit	$-2.4M	↓ 93.99%

	FY22	Y/Y Change
Profit	$838.0K	↓ 134.74%

	FY23	Y/Y Change
Profit	$6.0M	↑ 615.04%

	FY24	Y/Y Change
Profit	$5.5M	↓ 8.06%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$4.8M	↑ 202.51%

	Q2 FY24	Q/Q Change
Profit	$-14.2M	↓ 393.98%

	Q3 FY24	Q/Q Change
Profit	$1.1M	↓ 108.06%

	Q4 FY24	Q/Q Change
Profit	$8.2M	↑ 618.76%

	Q1 FY25	Q/Q Change
Profit	$1.2M	↓ 85.1%

	Q2 FY25	Q/Q Change
Profit	$1.8M	↑ 47.63%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-26.3M	↑ 166.85%
Investing Cash Flow	$-508.0K	↑ 75.17%
Financing Cash Flow	$48.6M	↑ 154.67%

	FY20	Y/Y Change
Operating Cash Flow	$-47.3M	↑ 79.58%
Investing Cash Flow	$-20.6M	↑ 3953.54%
Financing Cash Flow	$39.6M	↓ 18.57%

	FY21	Y/Y Change
Operating Cash Flow	$-57.1M	↑ 20.63%
Investing Cash Flow	$-232.2M	↑ 1027.63%
Financing Cash Flow	$311.1M	↑ 685.69%

	FY22	Y/Y Change
Operating Cash Flow	$-76.5M	↑ 34.06%
Investing Cash Flow	$57.9M	↓ 124.92%
Financing Cash Flow	$503.0K	↓ 99.84%

	FY23	Y/Y Change
Operating Cash Flow	$-69.5M	↓ 9.12%
Investing Cash Flow	$71.0M	↑ 22.77%
Financing Cash Flow	$253.0K	↓ 49.7%

	FY24	Y/Y Change
Operating Cash Flow	$-61.3M	↓ 11.85%
Investing Cash Flow	$57.6M	↓ 18.95%
Financing Cash Flow	$108.0K	↓ 57.31%

Q2 FY24

Q3 FY24

Q4 FY24

Q2 FY25

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-16.1M	↓ 3.64%
Investing Cash Flow	$18.0M	↑ 76.45%
Financing Cash Flow	$79.0K	-

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-14.0M	↓ 13.48%
Investing Cash Flow	$17.1M	↓ 4.8%
Financing Cash Flow	$0.0	↓ 100.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-14.4M	↑ 3.32%
Investing Cash Flow	$12.2M	↓ 28.63%
Financing Cash Flow	$29.0K	-

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-9.6M	↓ 28.19%
Investing Cash Flow	$10.8M	↓ 25.83%
Financing Cash Flow	$14.0K	-

Bolt Biotherapeutics Technicals Summary

Sell

Neutral

Buy

Bolt Biotherapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Bolt Biotherapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bolt Biotherapeutics Inc	-6.15%	-41.25%	-61.83%	-85.58%	-99.19%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	2.49%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bolt Biotherapeutics Inc	NA	NA	NA	-16.17	-0.81	-0.33	NA	20.24
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bolt Biotherapeutics Inc	Buy	$10.3M	-99.19%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Bolt Biotherapeutics Inc

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Organization	Bolt Biotherapeutics
Employees	52
CEO	Mr. William P. Quinn
Industry	Healthcare

Key Management of Bolt Biotherapeutics Inc

Name	Title
Mr. William P. Quinn	CEO, CFO, President, Secretary & Director
Mr. Grant Yonehiro C.F.A., M.B.A.	COO & Chief Business Officer
Ms. Sarah Nemec	Senior VP of Finance & Principal Accounting Officer
Mr. Wesley Burwell	VP & Head of Human Resources
Dr. Nathan Ihle Ph.D.	Senior Vice President of Pharmaceutical Operations
Dr. Michael N. Alonso Ph.D.	Senior Vice President of Research
Mr. Justin Kenkel	Senior Principal Scientist

Important FAQs about investing in BOLT Stock from India :

What is Bolt Biotherapeutics share price today?

Bolt Biotherapeutics share price today is $5.13 as on August 30, 2025 at 1:29 am IST at the close of the market. Bolt Biotherapeutics share today touched a day high of $5.19 and a low of $5.13.

What is the 52 week high and 52 week low for Bolt Biotherapeutics share?

Bolt Biotherapeutics share touched a 52 week high of $14.36 and a 52 week low of $4.59. Bolt Biotherapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $5.13, lower by 64.28% versus the 52 week high.

How to invest in Bolt Biotherapeutics Stock (BOLT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Bolt Biotherapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Bolt Biotherapeutics Shares that will get you 0.2924 shares as per Bolt Biotherapeutics share price of $5.13 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Bolt Biotherapeutics Stock (BOLT) from India?

Indian investors can start investing in Bolt Biotherapeutics (BOLT) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Bolt Biotherapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Bolt Biotherapeutics share’s latest price of $5.13 as on August 30, 2025 at 1:29 am IST, you will get 1.9493 shares of Bolt Biotherapeutics. Learn more about fractional shares .

What are the returns that Bolt Biotherapeutics has given to Indian investors in the last 5 years?

Bolt Biotherapeutics stock has given -99.19% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?